XML 54 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue Recognition - Contract Balances - Additional Information (Details)
 1 Months Ended 6 Months Ended
Oct. 31, 2023
USD ($)
Aug. 31, 2022
USD ($)
Jun. 30, 2024
USD ($)
Obligation
Dec. 31, 2023
USD ($)
Aug. 31, 2023
USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]          
Accounts receivable     $ 0 $ 0  
Contract liabilities     $ 0 $ 0  
Reimbursement period of costs incurred for quarter ended     75 days    
GSK          
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]          
Reimbursement period of costs incurred for quarter ended     75 days    
GSK Collaboration Agreement          
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]          
Number of performance obligations | Obligation     6    
Pol Theta Program          
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]          
Additional milestone payment potentially received clinical evaluation     $ 10,000,000    
Milestone payment received for achievement of earlier preclinical development milestone   $ 3,000,000      
Milestone payment received clinical evaluation         $ 7,000,000
Reimbursement period of costs incurred for quarter ended     90 days    
WRN Program          
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]          
Milestone payment received for achievement of earlier preclinical development milestone $ 3,000,000        
Milestone payment received clinical evaluation $ 3,000,000        
Reimbursement period of costs incurred for quarter ended     75 days    
Determination period of costs incurred     75 days